31 October 2023 - Today, US Department of Health and Human Services Secretary Xavier Becerra released the following statement regarding the FDA’s approval of Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases:

"Americans pay too much for prescription drugs. Lack of affordable access to prescription drugs and other health care services leads to worse health outcomes. That is why the Biden-Harris Administration has made it a top priority to lower health care costs and make sure every American has access to affordable, high quality health care. Increasing competition and the availability of lower cost biosimilars for high-cost prescription drugs is a key part of that effort.

Read Health and Human Services press release